Research Topics
Species | Kei MuroSummaryAffiliation: Aichi Cancer Center Country: Japan Publications
| Collaborators
|
Detail Information
Publications
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)Kei Muro
Department of Clinical Oncology, Aichi Cancer Centre Hospital, Chikusa ku, Nagoya, Japan
Lancet Oncol 11:853-60. 2010....
A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancerKei Muro
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Jpn J Clin Oncol 39:321-6. 2009..This Phase 2 study evaluated efficacy, pharmacokinetics and safety of panitumumab in Japanese patients with mCRC who developed progressive disease during or after fluoropyrimidine, irinotecan and oxaliplatin chemotherapy...
Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancerTomoya Yokota
Department of Clinical Oncology, Aichi Cancer Center Hospital, Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
Anticancer Res 31:3535-41. 2011..This study aimed to evaluate the efficacy of docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer...
Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapyMotoo Nomura
Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan
Int J Radiat Oncol Biol Phys 82:946-52. 2012..The objective of this study was to evaluate the prognostic impact of the new staging system on esophageal cancer patients treated with CRT...
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eatKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Oncology 79:211-8. 2010..However, these studies included patients able to maintain sufficient oral intake, and the effectiveness of chemotherapy for patients unable to eat remained unclear...
Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapyKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan
Asian Pac J Cancer Prev 11:447-52. 2010..The purpose of this analysis was to evaluate the impact of genetic polymorphisms of the ABCB1 gene on clinical outcomes in patients with advanced gastric cancer (AGC) treated with second-line chemotherapy...
Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancerKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi 464 8681, Japan
Gastric Cancer 14:155-60. 2011....
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRASKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, 464 8681, Aichi, Japan
Invest New Drugs 29:688-93. 2011..1 months. Grade 2 skin toxicity was observed in 23 patients, while no grade 3 skin toxicity was observed. Combined irinotecan and cetuximab is effective for pretreated metastatic wild-type KRAS colorectal cancer...
FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastasesAyako Mizota
Dept of Clinical Oncology, Aichi Cancer Center Hospital, Japan
Gan To Kagaku Ryoho 38:1205-8. 2011..Combination chemotherapy with mFOLFOX6 plus cetuximab was effective and feasible in this case of metastatic colon cancer with icterus due to diffuse liver metastasis...
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRASKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Jpn J Clin Oncol 40:699-701. 2010..The primary endpoint is response rate. The secondary endpoints include adverse events, progression-free survival and overall survival. The pharmacokinetics of cetuximab will also be evaluated in five patients...
Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancerAyako Mizota
Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 0011, Japan
Int J Clin Oncol 16:416-20. 2011..The efficacy and safety of cetuximab for irinotecan-intolerant patients has not yet been evaluated in detail...
Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumabKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Aichi, Japan
Jpn J Clin Oncol 41:663-5. 2011..In this case, trastuzumab plus lapatinib resulted in durable stable disease, despite the appearance of progression during prior chemotherapy with trastuzumab...
Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOXKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Eur J Cancer 45:1757-63. 2009..Prospective trials are required to assess whether dosing adjustments based on neutropaenia may improve chemotherapy efficacy...
Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapyKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
Cancer Chemother Pharmacol 68:301-7. 2011..We performed a systematic review and meta-analysis to determine the impact of neutropenia or leukopenia experienced during chemotherapy on survival...
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidinesKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi Prefecture 464 8681, Japan
Invest New Drugs 30:787-93. 2012..0%) and one treatment related death due to pneumonia was observed. Combination chemotherapy with biweekly cetuximab and irinotecan was effective for pretreated metastatic colorectal cancer with wild-type KRAS...
[Transition of chemotherapy for metastatic colorectal cancer and recent advances]Kei Muro
Department of Clinical Oncology, Aichi Cancer Center Hospital
Nihon Rinsho 68:1143-9. 2010..By continued advances in pharmaceutical development combined with appropriate use of liver resection, we hope that these gains may be amplified and extended to further improve patient survival...
Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancerKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, and Department of Epidemiology, Nagoya University Graduate School of Medicine, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Aichi, Japan
Cancer Epidemiol Biomarkers Prev 19:1311-9. 2010..However, to our knowledge, there are no reports that evaluate simultaneously the effects of folate intake and genetic polymorphisms on clinical outcome of gastric cancer patients...
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancerKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Eur J Cancer 47:2673-80. 2011....
Randomized phase II study comparing dose escalated weekly paclitaxel vs. standard dose weekly paclitaxel for patients with previously treated advanced gastric cancerKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Aichi, Japan
Jpn J Clin Oncol 41:287-90. 2011..The primary endpoint is overall survival. Secondary endpoints include progression-free survival, response rate, disease control rate and adverse events...
A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumabAyako Mizota
Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
Int J Clin Oncol 16:766-9. 2011..This case suggests that reintroduction of combination chemotherapy with FOLFOX plus bevacizumab is effective and feasible in patients with colorectal cancer with DIC and that chemotherapy may be a treatment option for such patients...
Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgeryKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
Oncology 81:167-74. 2011..The ability of molecular targeting agents to improve overall survival (OS) in metastatic colorectal cancer (MCRC) patients who underwent oxaliplatin-based chemotherapy remains controversial...
Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related ComplicationsKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
Case Rep Oncol 3:282-6. 2010..Therefore, FOLFOX plus cetuximab is suspected to be the best regimen to alleviate tumor-related symptoms with a high response rate...
A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapyAyako Mizota
Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
Oncology 81:237-42. 2011..To retrospectively compare docetaxel (DTX) with paclitaxel (PTX) with regard to efficacy and safety in advanced or recurrent esophageal cancer patients who previously received platinum-based chemotherapy...
[Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey]Yumiko Sato
Department of Pharmacy, West Medical Center Municipal Hospital, Nagoya, Japan
Yakugaku Zasshi 131:1661-6. 2011..Information on such predictive factors should be useful to promote the effectiveness of cancer chemotherapy...
Chemotherapy for gastric cancer that recurs after adjuvant chemotherapy with S-1Kohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Jpn J Clin Oncol 38:786-9. 2008..3 versus 2.3 months, P = 0.02). S-1-containing chemotherapy does not appear to be effective in patients whose gastric cancer recurs after adjuvant S-1 chemotherapy. Other chemotherapeutic agents should be evaluated in this setting...
Central venous access port-related complications in outpatient chemotherapy for colorectal cancerYoshitaka Inaba
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, 1 1Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
Jpn J Clin Oncol 37:951-4. 2007..The port system has been placed more frequently since the approval of FOLFOX. Consequently, more complications involving ports and pumps have been encountered...
Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective studyKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan
Cancer Sci 101:1001-6. 2010..Further investigation is warranted to explain this different prognosis...
Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancerTomoya Yokota
Department of Clinical Oncology, Aichi Cancer Center Hospital, Kanokoden, Chikusa ku, Nagoya, Japan
Transl Res 156:98-105. 2010..In conclusion, cycleave PCR is practically applicable to KRAS/BRAF genotyping using small amounts of biopsied tumor cells. Care must be taken in the selection of pathological specimens for KRAS/BRAF testing...
[Molecular targeted therapy in colorectal cancer and its resistance]Kohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan
Gan To Kagaku Ryoho 36:557-66. 2009..Further basic research and biomarker analysis of large clinical study are necessary to clarify the resistance to molecular targeting agents...
Dramatic tumor response to everolimus for malignant epithelioid angiomyolipomaKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Aichi, Japan
Jpn J Clin Oncol 41:814-6. 2011..In this case, treatment with everolimus resulted in dramatic tumor response for the malignant epithelioid variant of angiomyolipoma...
Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in JapaneseKeitaro Matsuo
Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
Int J Cancer 125:1961-4. 2009..No association was seen between PSCA polymorphisms and H. pylori infection. In conclusion, PSCA polymorphisms are associated with stomach cancer risk in Japanese. A possible interaction with family history warrants further evaluation...
Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectivesKohei Shitara
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Gastrointest Cancer Res 3:66-72. 2009..Additional studies are necessary to further elucidate this multimodality approach. Current treatment strategies for esophageal cancer and research initiatives in Japan are reviewed...
[mTOR inhibitor]Kei Muro
Dept of Clinical Oncology, Aichi Cancer Center Hospital, Japan
Gan To Kagaku Ryoho 38:7-11. 2011..The usefulness of mTOR has also been shown in pancreatic neuroendocrine tumor. The next task is to discover a clinically effective biomarker that predicts effect and toxicity of mTOR...
